The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Vitamin K and cancer

På svenska

Author

Summary, in English

Subclinical vitamin K deficits refer to carboxylation defects of different types of vitamin K-dependent hepatic and extrahepatic so-called Gla proteins without prolongation of the prothrombin time. This condition has been reported in different clinical situations due to insufficient supply or malabsorption of vitamin K as well as drug interactions. This review discusses the effects of different vitamin K subspecies on tumour growth and the possible anti-tumour effects of increased vitamin K intake. Blocking carboxylation of vitamin K-dependent proteins with warfarin anticoagulation – what are the risks/benefits for carcinogenesis? Previous studies on both heparin and low molecular weight heparin blocking of the vitamin K-dependent factors X and II have shown tumour suppressive effects. Vitamin K has anti-inflammatory effects that could also impact carcinogenesis, but little data exists on this subject.

Publishing year

2017-09-21

Language

English

Pages

555-567

Publication/Series

Scandinavian Journal of Clinical and Laboratory Investigation

Volume

77

Issue

8

Document type

Journal article

Publisher

Informa Healthcare

Topic

  • Cancer and Oncology

Keywords

  • anticoagulants
  • apoptosis
  • cell cycle checkpoints
  • growth arrest-specific protein 6
  • matrix Gla protein
  • neoplasm
  • osteocalcin
  • PIVKA-II
  • steroid and xenobiotic receptor
  • Vitamin K

Status

Published

Project

  • Koagulation vid kirurgi och kritisk sjukdom

Research group

  • Clinical Research in Anaesthesia and Intensive Care Medicine

ISBN/ISSN/Other

  • ISSN: 0036-5513